Atlantic Union Bankshares Corp Has $2 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Atlantic Union Bankshares Corp trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 75,404 shares of the biopharmaceutical company’s stock after selling 8,764 shares during the period. Atlantic Union Bankshares Corp’s holdings in Pfizer were worth $2,000,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Swedbank AB grew its stake in Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares in the last quarter. Beckerman Institutional LLC purchased a new position in Pfizer in the third quarter valued at about $376,000. Equitable Trust Co. grew its stake in Pfizer by 4.6% in the third quarter. Equitable Trust Co. now owns 50,745 shares of the biopharmaceutical company’s stock valued at $1,469,000 after purchasing an additional 2,242 shares in the last quarter. CWA Asset Management Group LLC purchased a new position in Pfizer in the third quarter valued at about $1,382,000. Finally, Holistic Planning LLC grew its stake in Pfizer by 215.8% in the third quarter. Holistic Planning LLC now owns 46,364 shares of the biopharmaceutical company’s stock valued at $1,342,000 after purchasing an additional 31,681 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Pfizer Trading Up 1.8 %

Pfizer stock opened at $26.71 on Friday. The business has a 50 day moving average price of $26.30 and a two-hundred day moving average price of $27.24. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $151.35 billion, a price-to-earnings ratio of 18.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, January 24th were issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.44%. Pfizer’s dividend payout ratio is 121.99%.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.